Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Cardiology

Diagnostic Imaging and Biopsy

At a Glance

For suspected viral dilated cardiomyopathy, cardiac MRI is the preferred noninvasive test for heart swelling, injury, and scarring, but it cannot prove which virus caused the problem. An endomyocardial biopsy is reserved for unstable or rapidly worsening cases when results could change treatment.

The diagnostic process for viral dilated cardiomyopathy (viral DCM) is like piecing together a puzzle. While an initial ultrasound (echocardiogram) can show that the heart is weak or enlarged, it cannot see the “why.” To understand if a virus or your immune system is the cause, doctors use specialized imaging and, in specific cases, a tissue sample from the heart muscle [1][2]. Importantly, myocarditis or nonischemic DCM requires evaluation for alternative causes, such as coronary disease, genetic variants, toxins, or autoimmune conditions.

The Preferred Non-Invasive Test: Cardiac MRI

A Cardiac MRI (CMR) is the preferred non-invasive tool for evaluating suspected myocarditis and characterizing inflammation and scar [3]. While a CMR cannot identify a specific virus or prove a viral cause, it can distinguish between different types of tissue, such as healthy muscle, swollen muscle, and scarred muscle [4].

The Lake Louise Criteria

Radiologists use a specific set of rules called the Lake Louise Criteria to help decide if your heart is currently inflamed. To meet these criteria, the scan looks for two main things:

  1. Edema (Swelling): This is measured using T2 mapping or T2-weighted images. It shows that the heart muscle is currently holding extra fluid, which can suggest acute injury or inflammation [4][5].
  2. Myocardial Injury: This is measured using T1 mapping or Late Gadolinium Enhancement (LGE). It shows that the cells have been damaged or replaced by scar tissue [5][6].

Understanding “LGE” (The Scar Marker)

During the MRI, a contrast agent called gadolinium is injected. If the heart muscle is healthy, it washes out quickly. If there is damage or scarring, the gadolinium gets trapped and “lights up” late in the scan—this is Late Gadolinium Enhancement (LGE) [7].

  • What it means: In the acute (early) phase, LGE can represent temporary inflammation or injury. However, in chronic DCM, LGE usually represents fibrosis (permanent scarring) [8][9].
  • Prognosis: The amount and location of LGE (such as in the septum) help doctors assess your risk for irregular heart rhythms (arrhythmias), though LGE must be interpreted along with your overall clinical picture [10][11].

Endomyocardial Biopsy (EMB): The Deep Dive

An Endomyocardial Biopsy (EMB) is a procedure where a small piece of heart tissue is removed using a thin tube. This is not a routine test for everyone. Because it is invasive, it is typically reserved for high-risk or confusing situations when the result is likely to change your medical treatment [12][13].

When is a biopsy necessary?

According to current medical guidelines, a biopsy is most often recommended if:

  • You are “unstable,” meaning your blood pressure is dangerously low or you have life-threatening arrhythmias [12][14].
  • Your heart weakness is worsening rapidly despite standard medications [15].
  • Doctors suspect a rare type of inflammation (like Giant Cell or Eosinophilic Myocarditis) that requires a specific, aggressive treatment, or if immunosuppression is being contemplated [16][17].

What the lab looks for

Once the tissue is taken, it undergoes critical tests:

  1. Histology: Looking under a microscope for signs of cell death and inflammation [18].
  2. Immunohistochemistry (IHC): Using special stains to count exactly how many white blood cells are in the heart muscle to define the level of active inflammation [19][20].
  3. Viral PCR: A molecular test to find the DNA or RNA of viruses. This tells the doctor which virus is present, though it doesn’t always prove the virus is the active cause [21][22].

Completeness Checklist

When reviewing your reports, these are examples of details that guide interpretation. Because of sampling error (the needle might miss the inflamed patch of tissue), your doctors will interpret these alongside your symptoms.

Test Type What to Look For in the Report
Cardiac MRI T1 & T2 Mapping: Were both performed to check for swelling and injury?
LGE Pattern: Is it “subepicardial” (outer wall) or “mid-wall”? (This helps evaluate myocarditis vs. other conditions like coronary disease).
Extracellular Volume (ECV): A measure of how much “extra space” (scar/fluid) is in the muscle.
Biopsy Sample Count: The number of samples taken (multiple samples reduce the risk of sampling error) [19].
IHC Count: The number of leukocytes per mm² (helps classify the level of inflammation) [18].
Viral Load: Does the PCR report name a specific virus?

Common questions in this guide

What can a cardiac MRI show in viral dilated cardiomyopathy?
A cardiac MRI can show whether the heart muscle is swollen, injured, or scarred and can reveal patterns that help distinguish myocarditis from some other causes. It cannot identify a specific virus or by itself prove that a virus caused the cardiomyopathy.
What do the Lake Louise criteria mean on a cardiac MRI?
These criteria use signs of swelling, measured with T2 mapping or T2-weighted images, and signs of muscle injury, measured with T1 mapping or late gadolinium enhancement. Meeting the criteria supports active heart-muscle inflammation, but doctors interpret the result with symptoms and other tests.
Does LGE on my MRI mean permanent scarring?
LGE means gadolinium remained in areas of heart-muscle injury or scar. In an early illness it can reflect temporary inflammation or injury, while in chronic dilated cardiomyopathy it more often represents fibrosis, or permanent scar; its amount and location can help estimate arrhythmia risk.
When is an endomyocardial biopsy needed for viral DCM?
Biopsy is not a routine test for everyone. It is usually considered when a person is unstable, has life-threatening arrhythmias, worsens quickly despite standard medicines, or may have a rare form of myocarditis for which the result would change treatment.
What can doctors learn from a heart-muscle biopsy?
Pathology testing can look for cell death and inflammation, special stains can count inflammatory white blood cells, and viral PCR can look for viral DNA or RNA. Finding viral material does not always prove that the virus is actively causing the heart injury.
Can a negative biopsy rule out myocarditis?
Not necessarily, because a biopsy samples only a small area and may miss a patch of inflamed tissue. Doctors combine the biopsy with cardiac MRI, symptoms, and other test results when deciding what the findings mean.
Why do doctors look for other causes besides a virus?
A weak or enlarged heart can have causes such as coronary artery disease, genetic variants, toxins, or autoimmune conditions. Cardiac MRI and biopsy findings must be interpreted alongside tests for these alternatives because an MRI cannot prove a specific viral cause.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my Cardiac MRI, were the Lake Louise Criteria met for acute inflammation?
  2. 2.Did my MRI show only 'edema' (swelling) or also 'LGE' (scarring), and what does the pattern of that scarring say about my prognosis?
  3. 3.If I need an endomyocardial biopsy, will the tissue be tested for both the presence of a virus (PCR) and active inflammation (IHC)?
  4. 4.Why is a biopsy being recommended (or not recommended) for my specific situation?
  5. 5.What alternative causes for my heart weakness (like blockages or genetic variants) have we evaluated?
  6. 6.If a virus was found in my heart, is there evidence that it is 'active' and replicating, or could it be a 'bystander'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Myocarditis and pericarditis in focus: A critical appraisal of the 2025 ESC vs ACC position statements from the Italian society of cardiology working group on cardiomyopathies and pericardial diseases.

    Imazio M, Collini V, Merlo M, et al.

    Trends in cardiovascular medicine 2026; (36(5)):317-326 doi:10.1016/j.tcm.2026.01.002.

    PMID: 41534803
  2. 2

    Parametric Mapping Cardiac Magnetic Resonance Imaging for the Diagnosis of Myocarditis in Children in the Era of COVID-19 and MIS-C.

    Das BB, Akam-Venkata J, Abdulkarim M, Hussain T

    Children (Basel, Switzerland) 2022; (9(7)) doi:10.3390/children9071061.

    PMID: 35884045
  3. 3

    [IRM et myocardite infectieuse].

    Sanguineti F, Garot J, Hovasse T, et al.

    Annales de cardiologie et d'angeiologie 2020; (69(6)):418-423 doi:10.1016/j.ancard.2020.09.043.

    PMID: 33069385
  4. 4

    Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations.

    Ferreira VM, Schulz-Menger J, Holmvang G, et al.

    Journal of the American College of Cardiology 2018; (72(24)):3158-3176 doi:10.1016/j.jacc.2018.09.072.

    PMID: 30545455
  5. 5

    Cardiac inflammation and fibrosis patterns in systemic sclerosis, evaluated by magnetic resonance imaging: An update.

    Mavrogeni S, Pepe A, Gargani L, et al.

    Seminars in arthritis and rheumatism 2023; (58()):152126 doi:10.1016/j.semarthrit.2022.152126.

    PMID: 36434895
  6. 6

    Prognostic Implications of Clinical and Imaging Diagnostic Criteria for Myocarditis.

    Bernhard B, Marxer ME, Zurkirchen JC, et al.

    Journal of the American College of Cardiology 2024; (84(15)):1373-1387 doi:10.1016/j.jacc.2024.07.018.

    PMID: 39357935
  7. 7

    Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies.

    Aquaro GD, De Gori C, Faggioni L, et al.

    European heart journal supplements : journal of the European Society of Cardiology 2023; (25(Suppl C)):C130-C136 doi:10.1093/eurheartjsupp/suad015.

    PMID: 37125322
  8. 8

    Recent Advances in T1 and T2 Mapping in the Assessment of Fulminant Myocarditis by Cardiac Magnetic Resonance.

    Wheen P, Armstrong R, Daly CA

    Current cardiology reports 2020; (22(7)):47 doi:10.1007/s11886-020-01295-0.

    PMID: 32472218
  9. 9

    Utilization of Cardiac Magnetic Resonance Imaging for Assessing Myocardial Fibrosis in Prognosis Evaluation and Risk Stratification of Patients with Dilated Cardiomyopathy.

    Feng XY, Zheng YC, Yang YX, et al.

    Reviews in cardiovascular medicine 2025; (26(1)):25654 doi:10.31083/RCM25654.

    PMID: 39867184
  10. 10

    Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis.

    Di Marco A, Anguera I, Schmitt M, et al.

    JACC. Heart failure 2017; (5(1)):28-38 doi:10.1016/j.jchf.2016.09.017.

    PMID: 28017348
  11. 11

    The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis.

    Yang F, Wang J, Li W, et al.

    European radiology 2020; (30(5)):2616-2626 doi:10.1007/s00330-019-06643-5.

    PMID: 32040731
  12. 12

    Myocarditis and Chronic Inflammatory Cardiomyopathy, from Acute Inflammation to Chronic Inflammatory Damage: An Update on Pathophysiology and Diagnosis.

    Uccello G, Bonacchi G, Rossi VA, et al.

    Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010150.

    PMID: 38202158
  13. 13

    Immunosuppressive therapy in patients with biopsy-proven inflammatory myocardial disease: a systematic review and meta-analysis.

    Stautner B, Tkaczyszyn M, Sorg A, et al.

    Scientific reports 2025; (15(1)):37173 doi:10.1038/s41598-025-25165-3.

    PMID: 41131323
  14. 14

    Fulminant myocarditis proven by early biopsy and outcomes.

    Huang F, Ammirati E, Ponnaiah M, et al.

    European heart journal 2023; (44(48)):5110-5124 doi:10.1093/eurheartj/ehad707.

    PMID: 37941449
  15. 15

    Acute myocarditis: 2024 state of the art.

    Ammirati E, Cartella I, Varrenti M, et al.

    European heart journal supplements : journal of the European Society of Cardiology 2025; (27(Suppl 1)):i56-i60 doi:10.1093/eurheartjsupp/suae105.

    PMID: 39980767
  16. 16

    The State of the Heart Biopsy: A Clinical Review.

    Kiamanesh O, Toma M

    CJC open 2021; (3(4)):524-531 doi:10.1016/j.cjco.2020.11.017.

    PMID: 34027357
  17. 17

    Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week.

    Bang V, Ganatra S, Shah SP, et al.

    Journal of the American College of Cardiology 2021; (77(8)):1122-1134 doi:10.1016/j.jacc.2020.11.074.

    PMID: 33632487
  18. 18

    Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection.

    Caforio ALP, Baritussio A, Basso C, Marcolongo R

    Annual review of medicine 2022; (73()):149-166 doi:10.1146/annurev-med-042220-023859.

    PMID: 34506211
  19. 19

    Biventricular endomyocardial biopsy in patients with suspected myocarditis: Feasibility, complication rate and additional diagnostic value.

    Stiermaier T, Föhrenbach F, Klingel K, et al.

    International journal of cardiology 2017; (230()):364-370 doi:10.1016/j.ijcard.2016.12.103.

    PMID: 28040278
  20. 20

    A case of chronic myocarditis.

    Kawano H, Iyama K, Abe K, et al.

    Pathology international 2020; (70(10)):793-797 doi:10.1111/pin.12989.

    PMID: 32716103
  21. 21

    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.

    Sinagra G, Porcari A, Gentile P, et al.

    European journal of heart failure 2021; (23(2)):211-216 doi:10.1002/ejhf.1969.

    PMID: 32683758
  22. 22

    The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention.

    Elsanhoury A, Kühl U, Stautner B, et al.

    Viruses 2022; (14(2)) doi:10.3390/v14020299.

    PMID: 35215893

This page explains cardiac MRI and endomyocardial biopsy in viral dilated cardiomyopathy for informational purposes only and does not constitute medical advice. Your cardiology team should interpret your results and decide whether a biopsy or other tests are appropriate.

Get notified when new evidence is published on viral dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.